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Gene editing can be used to overcome allo-recognition which otherwise limits allogeneic 
T cell therapies. Initial proof-of-concept applications have included generation of such 
‘universal’ T cells expressing chimeric antigen receptors (CAR) against CD19 target 
antigens combined with transient expression of DNA-targeting nucleases to disrupt the T 
cell receptor alpha constant chain (TRAC). While relatively efficient, transgene 
expression and editing effects were unlinked, yields variable, and resulting T cell 
populations heterogeneous, complicating dosing strategies. We describe a self-
inactivating lentiviral ‘terminal’ vector platform coupling CAR expression with 
CRISPR/Cas9 effects through incorporation of an sgRNA element into the ∆U3 3’ long 
terminal repeat (LTR). Following reverse transcription and duplication of the hybrid ∆U3-
sgRNA, delivery of Cas9 mRNA resulted in targeted TRAC locus cleavage and allowed 
the enrichment of highly homogenous (>96%) CAR+ (>99%) TCR- populations by 
automated magnetic separation. Molecular analyses, including NGS, WGS and 
Digenome-seq verified on-target specificity with no evidence of predicted off-target 
events. Robust anti-leukemic effects were demonstrated in humanized immunodeficient 
mice and were sustained longer than by conventional CAR+TCR+ T cells. Terminal-
TRAC (TT) CAR T cells offer the possibility of a pre-manufactured, non-HLA matched 



















T cells engineered to express recombinant antigen specific receptors or chimeric antigen 
receptors are in multi-phase trials, with some approaches yielding compelling remission 
effects against refractory leukemia.1 The majority of subjects treated to date have 
provided and received autologous T cells, but this approach may not be best suited for 
widespread cost-effective delivery of cellular therapy. Gene editing offers the prospect of 
addressing HLA- barriers and the development of universal T cell therapies.2, 3 Recently T 
cells modified using transcription activator-like effector nucleases (TALENs) and 
expressing chimeric antigen receptor (CAR) against CD19 have been used to treat 
refractory relapsed B cell acute lymphoblastic leukemia (B-ALL) in infants.4 These ‘off-
the-shelf’ cells were derived from a non-HLA matched donor and were disrupted for 
CD52 expression to evade the depletion effects of Alemtuzumab, and were 
simultaneously modified at the T cell receptor (TCR) alpha chain constant (TRAC) region 
and depleted of T cells expressing TCRαβ to reduce the risk of graft versus host disease 
(GVHD).5 Clinical trials are underway to assess the strategy further in children and adults, 
and key aspects determining dosing schedules related to carriage of residual TCRαβ T 
cells and proportion of cells expressing CAR19. The former comprise <1% of the total 
cell inoculum after TCRαβ magnetic bead depletion, but constitute a risk for GVHD and 
are strictly capped to below 5x104 T cells/kg.6 This in turn limits the total cell dose, and 
because only a proportion of cells express CAR19 as a result of batch-to-batch variation 
in lentiviral transduction efficiency, the total cell dosing regimen differs between batches.  
Similar issues arise for other gene editing platforms relying on segregated DNA nuclease 
delivery, whether by non-integrating viral delivery of Zinc Finger Nucleases 3 or 

















We designed a self-inactivating (SIN)-lentiviral platform that coupled transgene 
expression with clustered regularly interspersed short palindromic repeats (CRISPR) 
editing effects for efficient and homogenous T cell modification (Figure 1A), and 
demonstrated that this system is scalable and can be incorporated into a largely automated 
manufacturing process. CRISPR mediated effects in CAR19 modified T cells have been 
reported previously. For example, Ren et al used CRISPR RNA electroporation to disrupt 
endogenous TCR and β2-microglobulin (B2m) genes for disruption of MHC class I in T 
cells transduced with a lentiviral CAR vector, but editing and transgene effects were 
unlinked.8, 9 Other lentiviral configurations have incorporated both CRISPR guide 
sequences and Cas9 expression cassettes which become integrated into the target cell 
genome as a constituent of proviral vector DNA.10 While suitable for pre-clinical studies, 
constitutive expression of Cas9 would be problematic in human trials, not least because of 
its bacterial origin and likely immunogenicity. In order to overcome this issue, we 
delivered capped, polyadenylated, uridine modified Cas9 mRNA by electroporation to T 
cells that had been transduced with our ‘terminal-CRISPR’ lentiviral configuration. Here, 
CAR19 was expressed under the control of an internal human promoter and CRISPR 
guide sequences and associated H1/U6 promoters were incorporated into the U3 region of 
the 3’ long terminal repeat (LTR) sequence of the vector. Previous vector configurations 
using these flanking regions have included a γ-retroviral vector for expression of cDNA 
cassettes 11, and a lentiviral system encoding short hairpin RNA interference elements.12 
Modification of the LTR can impair retroviral titres, but has a number of advantages, 
including avoiding interference with internal promoters 13 and duplication of sequences 
cited in the U3 locus following reverse transcription. Here we adopt and refine this 
approach for CRISPR delivery, anticipating guide duplication and incorporation into the 

















expression. We demonstrate compliant scalability and the potential of the platform for the 
generation of ‘universal’ human T cells on a clinical scale. Potent anti-leukemic effects of 
TCR depleted CAR19 T cells were demonstrated in a human:murine chimeric tumor 
model. Multi-modal analysis confirmed highly efficient ‘on-target’ modifications with no 




















Design and construction of lentiviral terminal-TRAC (TT) guide RNA vectors 
Incorporation of a Pol III promoter and single-guide-RNA (sgRNA) sequence into the 3’ 
LTR of a U3 deleted third generation lentiviral vector, generated a self-duplicating 
CRISPR expression cassette (Figure 1B). A region immediately proximal to 3’ repeat (R) 
regions was selected to preserve reverse transcription mediated duplication to the 5’ LTR, 
resulting in a proviral form with both 5’ and 3’ flanking terminal CRISPR elements 
(Figure 1C). For targeting of endogenous TCR expression, a sgRNA sequence targeting 
the TRAC locus (specificity score 94/10014) was placed under the control of the human 
Pol III promoter, U6, followed by a sgRNA sequence specific for S.pyogenes Cas9, which 
was delivered separately as mRNA by electroporation (Figure 1D). The lentiviral vector 
encoded a chimeric antigen receptor (CAR19) under the control of an internal human 
PGK promoter. The concentrated vector titre of this ‘Terminal-TRAC’ configuration (TT-
hPGK-CAR19) was comparable to a conventional pCCL-hPGK-CAR19 vector 
(1.6x108/ml v 1.5x108/ml) indicating that inclusion of the sgRNA cassette in the 3’ LTR 
was not detrimental to vector titre, and supported comparable transduction efficiencies in 
primary T cells. Unique primer pairs amplified both 3’ and 5’ LTR regions in these cells 
(Figure 2A) and yielded the expected 392bp 3’ U5 reaction product from the pCCL-
hPGK-CAR19 transduced cells compared to a larger 755bp product from the TT-hPGK-
CAR19 transduced cells. A 742bp 5’ PCR product indicated duplication of the U6 
promoter-sgRNA-scaffold sequences in contrast to a 379bp conventional duplication 
product. Bands were extracted and sequences verified by Sanger sequencing. 
Furthermore, quantitative RT-PCR found that guide RNA expression peaked between 24 
and 72 hours after lentiviral transduction and thereafter remained stable during 


















Transient Cas9 mRNA delivery by electroporation to Terminal-TRAC T cells 
Previous lentiviral configurations have incorporated Cas9 expression cassettes, but this 
could promote immunogenicity and result in on-going scission effects, risking toxicity. 
Stabilized Cas9 mRNA (capped, polyadenylated, and uridine modified) was delivered by 
electroporation for transient effects in dividing T cells exposed to a single round of 
transduction with TT-hPGK-CAR19 vector. An interval of 3 days was found to be 
optimal for TRAC disruption (Figure 2C). Cas9 protein was detected by Western blot as a 
160kDa protein band, with peak expression at 12 hours after mRNA electroporation and 
clearance by 72 hours (Figure 2D). Titration of Cas9 mRNA mediated disruption of TCR 
expression exhibited saturation above 25µg/ml (Figure 2E). Molecular signatures of non-
homologous end joining (NHEJ) at the TRAC locus were confirmed by PCR sequencing 
across the target locus and TIDE analysis of the 772bp TRAC amplicon (Figure 2F). 
Crucially, almost all cells expressing CAR19 were found to have disrupted TCR 
expression, indicating CRISPR-Cas9 effects were coupled to transgene expression. 
 
Scalability of Terminal-TRAC T cell production 
A critical hurdle for CRISPR/Cas9 gene editing is scalability and compliance for 
therapeutic manufacturing. We adapted an automated T cell lentiviral transduction 
procedure using the CliniMacs Prodigy system to compare alongside conventional 
cultures in G-Rex flasks, and activated 1x108 lymphocytes from a thawed leukapheresis 
harvest ahead of lentiviral transduction with TT-hPGK-CAR19 vector at MOI 5 in the 
closed system tubing set (Figure 3A and Figure S1). After a further 72 hours, cells were 
removed from the device and electroporated with Cas9 mRNA, after which the cells were 

















expression was 62% in CD45+CD2+ cells and TCR knockout in CD45+CD2+CAR19+ 
cells was 77% (Figure 3B). Further processing by magnetic bead mediated depletion of 
residual TCRαβ cells yielded a highly purified population of TCR depleted cells (>99%), 
almost all (96.9%) of which were CAR19+ T cells with a vector copy number (VCN) of 
1.69 (Figure 3B). Disruption of the TRAC locus at the genomic level was verified by 
TIDE PCR (Figure 3C), which revealed NHEJ events of around 80% with next generation 
sequencing (NGS) detecting ‘on-target’ cleavage effects in 92% of sequence reads.  
Overall, a final cell yield of 2.9x109 TT-CAR19+TCR- T cells was produced, almost 30x 
the starting number, and sufficient to create therapeutic doses for over 20 average adult 
subjects. 
 
Terminal TRAC-CAR19+TCR- T cells efficiently target CD19+ cells in vitro 
The cytolytic potential of TT-CAR19+TCR- cells was assessed by in vitro cytotoxicity 
against 51Cr loaded CD19+ or CD19- SupT1 target cells. When normalized for CAR19+ 
cells, both TT-CAR19+TCR- cells and CAR19+TCR+ T cells exhibited comparable 
specific lysis of CD19+ Supt1 targets after 4 hours of co-culture, in contrast to non-
transduced CAR19-TCR+ control cells (P<0.0001) (Figure 3D). Specific lysis of another 
CD19+ tumor line, Daudi, was also documented for CAR19+TCR+ and TT-
CAR19+TCR- effectors and a 4-hour degranulation assay on this target cell line further 
corroborated the cytotoxicity data with 57% of CAR19+TCR- and 53% of CAR19+TCR+ 
cells upregulating CD107a expression (Figure 3E). Finally, a CBA assay recorded slightly 
increased cytokine production of IFNγ, TNF, IL-4 and IL-2 after 24 hours of co-culture 
with CD19+ Supt1 cells but not from CD19-Supt1 cells further confirming target specific 


















Characterisation of on- and off- target CRISPR effects. 
Previously, we reported that T cells modified with a combination of TRAC and CD52 
specific TALENs, exhibited translocation events involving the TRAC locus in around 4% 
of 500 interphase spreads using a dual-colour break-apart FISH probe for the TRAD locus 
(which incorporates the TRAC site)4. For TT-CAR19+ T cells, no breakpoints were 
identified within the sensitivity limits of the assay across 350 interphase spreads in Cas9 
treated and across 600 interphase spreads in non-treated cells (Figure 4A). Further 
investigations compared these two populations using three independent modalities, based 
on WGS, targeted NGS and Digenome-seq. Predicted on-target Indel modifications 
captured by Digenome-seq had a score of 82.9%, corroborated by targeted amplification 
of the TRAC locus and analysis of >35,000 reads by NGS which revealed an Indel 
frequency of 92.3% versus 0.00% in non-edited cells (Figure 4B-C, Table S1 and Figure 
S2). In comparison, estimates by TIDE- PCR and 30x WGS had yielded lower 
modification efficiencies of 79% and 54% respectively reflecting less informed analysis 
techniques and lower read depths. Comparing events at 49 in silico predicted off-target 
sites by WGS and NGS and across ten additional gene loci with 14q translocation 
phenomena known to be associated with T cell leukemias (TAL1, LCK, REL, MYC, 
NOTCH1, TLX1, THUMPD1, BCL11B, TCL1A, TCL1B), there was no notable 
differences between the modified and non-modified samples (Table S1). In addition, 
Digenome-seq captured a further 12 off-target sites, of which 8 were distinct not having 
been predicted in silico, with 3/12 showing DNA cleavage scores between 3.5%-16% 
(Figure 4C-D and Table S2). However, further NGS-based interrogation of these 12 sites 
in TT-CAR19+TCR- DNA did not detect genomic disruption (Figure 4D and Table S2). 
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thresholding on WGS data, identified a comparable number of SNVs, insertions and 
deletions in both Cas9 treated and non-treated cells (Figure 4E).  
Further analysis of ‘CRISPR-specific’ mutations in the WGS data, which considered 
sequences proximal to PAM motifs, found 61% of Indels were unique to TT-
CAR19+TCR- Cas9 treated samples compared to 39% of changes in non-treated cells 
(Figure 4F). Similarly, translocation frequency was comparable in both samples (Figure 
4G), with 57% of structural unique variants detected in Cas9 treated cells and 42% in 
non-treated samples (Figure 4H). Additional filtering of these sites identified 16 Cas9 
treated and 14 non-treated changes as precise changes. Interestingly, one unpredicted site 
appeared to have been the subject of unanticipated modification. Chr3:128630177-
128630178, encoding RPN1 was found to have a 15% frameshift associated Indel 
frequency (8/50 reads) compared to 0/33 control sample reads. This site was not identified 
by Digenome-seq analysis, and further interrogation of the RPN1 locus by NGS 
discounted these Indels, highlighting the limitations of low depth sequencing and 
emphasizing the need for multifaceted investigations. Importantly, at the cellular level, T 
cell function was preserved and there was no evidence of overt toxicity in the edited TT-
CAR19+TCR- product. 
 
Terminal TRAC T cell anti-leukemic activity in vivo 
A humanized murine model of leukemic clearance was used to assess in vivo function of 
engineered CAR19 T cells. NSG mice inoculated intravenously with 5x105 
CD19+EGFP+Luciferase+ Daudi cells were imaged after 3 days, and then in groups of 8 
animals, injected with either TT-CAR19+TCR-, CAR19+TCR+ or untransduced CAR19-
TCR+ effector cells. Serial bioluminescence imaging was performed on days 7, 10 and 
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There was rapid clearance of tumor in groups receiving CAR19+ T cells with negligible 
signal by day 14, in contrast to mice receiving non-transduced T cells or PBS 
(***P<0.001) (Figure 5A). Interestingly, TT-CAR19+TCR- (n=8) mediated clearance by 
day 14 was superior compared to clearance in CAR19+TCR+ T cells injected mice (n=8) 
(*P<0.05) based on bioluminescence quantification (Figure 5C). Flow cytometric analysis 
was undertaken for GFP+ Daudi cells and CD45+CD2+ effector T cell populations 
harvested from bone marrow of TT-CAR19+TCR- (n=4/8), CAR19+TCR+ (n=5/8), 
CAR19-TCR+ (n=5/8) and PBS (n=3/3) injected mice. By day 14, less than 0.01% 
(0.009% ±0.006%) of total marrow harvested from long bones of TT-CAR19+TCR- and 
<0.007% ±0.002% of CAR19+TCR+ injected mice expressed GFP Daudi cells indicating 
a highly significant (>45-fold) reduction compared to the 0.416% ±0.301% (*P<0.05) and 
0.336% ±0.246% tumor content detected in the marrow of CAR19-TCR+ and PBS 
control animals respectively (Figure 5E). 
By day 28, the remaining control CAR19-TCR+ animals had exhibited a further 125-fold 
increase in tumor burden and the mice were culled, revealing a low T cell to tumor ratio 
on flow analysis, despite a significant expansion of CD45+CD2+ T cells in the final two 
weeks. The remaining treatment groups were monitored until day 34 (Figure 5A). 
Radiance increased in the CAR19+TCR+ group but not the TT-CAR19+TCR- group 
(Figure 5C) during this period with bioluminescence signal appearing to localize in the 
bone marrow. This finding was supported by flow cytometry data which showed GFP+ 
Daudi cells in marrow had increased six fold in the CAR19+TCR+ group (*P<0.05) 
(Figure 5D-E). Interestingly, on further analysis, we found evidence of antigen escape 
with clearly demarcated populations of CD20+ GFP+ Daudi cells that had lost CD19+ 
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The TT-CAR19+TCR- group exhibited the highest levels of CAR19+ T cells at both 2 
and 5 weeks and had the lowest tumor burden (Figure 5E) retaining the highest T 
cell:tumor ratio throughout. In contrast, median CAR19 percentage was 34.5%  (32.3-
53.6) in CAR19+TCR+ treated mice at 2 weeks and this rose to 92.9% (47.4-93.9) by 5 
weeks consistent with notable expansion of transduced populations.  The intensity of 
CAR19 expression on flow cytometry was higher in the TCR- animals than TCR+, but the 
difference was not-significant. Interestingly, the TCR+ mice exhibited high levels (84.5% 
(55.6-89.8)) of the exhaustion marker PD-1 on T cells compared to 15.1% (8.2-20.4) at 
two weeks (Figure 5G). This was also documented in non-transduced CAR19-TCR+ 
controls where PD1 levels of 48.6% (37.6-49.9) at 2 weeks and 83.5% (34.9-99.1) at 4 
weeks had been observed in predominantly CD4+ but also CD8+ T cells. Of note, TT-
CAR19+TCR- effectors had the least exhausted phenotype with the lowest levels of PD1 






There is accumulating evidence for the efficacy of T cells engineered to express chimeric 
antigen receptors (CARs) against leukemia antigens such as CD19 in the management of 
relapsed B cell malignancies.1 As well as autologous T cells, HLA-matched allogeneic T 
cells from hematopoietic stem cell donors have been used and recently non-HLA matched 
‘universal’ CAR-T cells have entered clinical phase assessments.4 These cells were edited 
using TALENs to disrupt the TRAC locus to prevent GVHD and at the CD52 locus to 
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process employed a multiplex approach, delivering mRNA encoding two highly specific 
TALEN pairs by electroporation which conferred high frequency allele modification but 
was also associated with predicted and unpredicted translocation events of unknown 
significance. In the case of the TRAC locus, in most T cells allelic exclusion operates to 
ensure that only a single TCRαβ configuration is expressed, and therefore NHEJ mediated 
disruption of the active allele is theoretically sufficient to disrupt cell surface TCRαβ 
expression. Downstream processing using CliniMacs TCRαβ magnetic bead depletion 
ensures removal of residual TCRαβ+ cells and readily yields highly purified (>99%) 
TCRαβ- T cells. However, shortcomings of current TALEN based approaches includes 
variable lentiviral transduction efficiencies between batches, and in the absence of an 
enrichment strategy to ensure all cells are CAR19+, variations in total cell dosing required 
to achieve a particular CAR19 dose. In turn, the total T cell dose is a critical parameter 
that is determined, and limited by, the absolute number of residual TCRαβ cells that might 
be adoptively transferred as part of the total cell dose. Under existing approaches, TCRαβ- 
cells may be CAR19+ or CAR19-, but by coupling gene-editing effects to CAR19 
expression, the TT-CAR19 configuration yields highly purified T cells that are 
CAR19+TCRαβ-. This system has a number of advantages:- 1. The incorporation of the 
CRISPR guide into the 3’ LTR mitigates against interference effects and ensures intact 
transgene expression for highly efficient transduction and TRAC editing effects; 2. 
Coupling effects become fully manifest after the completion of downstream processing 
and depletion of residual TCRαβ cells, by which stage the product is highly homogeneous 
CAR19+TCRαβ- ; 3 Transient delivery and expression of Cas9 (as stabilized, reduced 
immunogenicity Cas9 mRNA) provides time-limited DNA cleavage effects and reduces 
the risk of immunogenicity and using this approach, manufacture of a single Cas9 mRNA 
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costs and saving time associated with the manufacture of bespoke raw materials for 
different CRISPR/Cas9 targets; 4. The process is readily incorporated into an automated 
manufacturing platform facilitating early clinical application.  
Investigations into on- and off target effects in TALEN edited T cells have 
previously reported translocations between TRAC and CD52 target sites of up to 1%, and 
we previously found around 4-5% of cells exhibited abnormal karyotypes with evidence 
of various TRAD translocations found on breakpoint FISH probe analysis.4 Similar 
analysis in TRAC modified TT-CAR19+TCR- T cells did not detect any similar 
segregation of these FISH probes, although the sensitivity limitations of FISH means that 
translocations may have occurred below the limits of detection. We used three different 
platforms to confirm TRAC specific activity and absence of off-target effects. Whole 
genome sequencing found comparable very low frequencies of Indel events across the 
genome, including exonic sequences, for both Cas9 treated and non-treated cells.  While 
there was increased detection of structural variants in the edited samples, interrogation of 
the highest ranking in silico predicted off-target sites found edited and non-edited samples 
to have a similar frequency of changes in both WGS and higher resolution NGS outputs. 
Similar findings were recorded across ten additional genes known to be sites of 14q 
translocations associated with T cell leukemia. There are a number of important caveats 
and limitations to the application of WGS for analysis of gene editing effects, including 
limited read depth. Digenome-seq has the capacity to detect low frequency events (0.1%-
1%) and the specificity of the TRAC guide sequence was validated with negligible off-
target effects that were further interrogated by NGS and also found to be absent in Cas9 
treated cells. Nuclease mediated effects below this level however, are difficult to confirm 
given the sequencing error rates.15, 16 A single unpredicted site in RPN1 was identified by 
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discounted upon further interrogation by NGS and by Digenome-seq. This highlights a 
potential limitation of relying on low depth sequencing platforms, and suggests that a 
multi-platform approach using tools such as Digenome-seq 17 GUIDE-seq 18 or Lentivirus 
capture 19 coupled with high resolution sequencing is paramount.  
Finally, in vivo modeling revealed that TT-CAR19 T cells mediated highly effective 
leukemic eradication with less evidence of exhaustion compared to conventional TCR 
expressing CAR19 T cells. The latter was unexpected given that characterization of 
CAR19 transduced populations by flow cytometry, cytokine array profiles and functional 
studies in vitro had not detected any notable differences between TCR depleted CAR19 
cells and conventional TCR+ CAR19 T cells. In human:murine chimeras bearing Daudi B 
cell leukemia tumor inoculations, animals dosed with TT-CAR19 T cells exhibited potent 
anti-leukemic effects without xenoreactive GVHD within the period of testing, and 
reduced upregulation of the exhaustion marker PD1 compared to control groups that had 
retained TCR expression. This is consistent with previous murine studies 20 and clinical 
trials of donor derived human CAR19 T cells where TCR mediated co-activation may 
drive exhaustion.21  
Interestingly, flow characterization of Daudi cell surface marking in mice treated with 
CAR19+TCR+ T cells revealed a notable proportion had clearly lost CD19 expression at 
the time of culling, and this was not evident in tumor cells recovered from control 
CAR19-TCR+ treated mice. This phenomenon is reminiscent of clinical reports from 
patients who relapsed with CD19 negative leukemia after a period of remission following 
CAR19 therapy and we speculate that CD19 tumor populations acquired a survival 
advantage and expanded in the face of CAR19 immunity, although the absence of similar 
expansions in TT-CAR19+TCR- treated mice requires further investigation with larger 
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One advantage of T cell engineering using integrating vector systems has been their 
apparent resistance to possible transformational events as a result of vector integration, 
and to date there have been no reports of human T cell insertional mutagenesis. Even in 
animals, vector mediated leukemiagenesis in T cells has rarely been encountered, and 
only in highly stressed artificial model systems.22 Similar resilience may be anticipated 
following gene-editing, although loci such as the TRAC site have known translocation 
associations with T cell leukemia. We screened such sites by WGS, and all were found to 
be intact. In the absence of informative animal models, cautious deployment and careful 
patient monitoring will be essential to determine risks in early phase trials. Similarly, 
modeling in immunodeficient mice is not representative of clinical scenarios where 
lymphodepleting conditioning is required to overcome host mediated rejection of non-
matched ‘universal’ T cells, but accumulating experience in clinical trails is helping to 
determine the intensity of such regimens.  
The terminal vector configuration described here utilized Streptococcus pyogenes Cas9 
but is readily adapted for other similar nucleases 15, 23-25, nickases 26, deactivated Cas 
systems 27, 28, or cytidine deamination linked enzymes 29. The proof of concept 
configuration described here has been adapted further to include multiple guide cassettes 
for multiplex modifications, including simultaneous B2m disruption to deplete MHC class 
I expression and PD-1 disruption to promote T cell invigoration. The platform could, with 
certain revisions, also be used for targeted CAR insertion into the TRAC locus as recently 
described using Adeno-Associated Virus.30 However, the first planned therapeutic 
applications will be more straightforward and will exploit coupling of CAR19 and TCRαβ 
depletion, as a bridging strategy to transplantation. Thereafter, multiple applications are 
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transgenes encoding receptors, selection markers or suicide genes need to be combined 
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Materials and Methods 
CRISPR-CAR vector system 
A third generation SIN lentiviral vector described previously 31 expressing a CAR19 
transgene was subjected to cloning incorporating a HIV-1 cPPT element and mutated 
WPRE for the expression of a CAR19 transgene under the control of a human 
phosphoglycerate kinase (PGK) promoter was subjected to site directed mutagenesis to 
remove BbsI, BsmbI and SapI restriction sites using a QuickChange Lightning Kit 
(210518, Agilent Technologies, Santa Clara, USA). U6 and H1 CRISPR guide cassettes 
were then cloned into the ∆U3 region of the 3’LTR using In-Fusion HD Cloning Plus 
(638909, Takara Bio Europe, Saint-Germain-en-Laye, France). BbsI restriction sites were 
then incorporated between the Pol III promoter and scaffold sequences to allow for 
efficient guide sequence substitution. GeneART synthesized CRISPR cassettes 
(ThermoFisher Scientific, Massachusetts, USA) based on the Zhang group Streptococcus 
pyogenes Cas9 scaffold sequence 10 were cloned into the ∆U3 region of the 3’LTR. 
Concentrated vector preparations were produced by transient transfection of 293T cells as 
previously described.32, 33 
 
Primary human lymphocyte culture and modification   
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque density 
gradient and subsequently activated with TransACT reagent (130-109-104, Miltenyi 
Biotech, Surrey, UK). Lymphocytes were cultured in TexMACS medium (130-097-196, 
Miltenyi Biotech) with 3% human AB serum (GEM-100-512-HI, Seralabs, Brussels, 
Belgium) and 100U/ml Proleukin IL-2 (Novartis, Surrey, UK). PBMCs were transduced 
with lentiviral vector 24 hours post activation at a multiplicity of infection (MOI) of 5 and 
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11 post activation, and were then cryopreserved in 90% FCS and 10% dimethylsulfoxide 
(DMSO). Scaled experiments Scaled experiments ultilized a semi-automated platform as 
recently described.34 Briefly, the T-cell transduction (TCT) program was adapted on the 
CliniMACS Prodigy using the Tubing Set TS520 (130-019-002, Miltenyi Biotec) and 
used cryopreserved leukapheresis harvests (Allcells, Alameda, USA) cultured in 
TexMACS GMP Medium (170-076-307, Miltenyi Biotec) supplemented with 3% human 
AB serum (Seralabs) and 20ng/ml MACS GMP Human Recombinant IL-2 (170-076-146, 
Miltenyi Biotec).34 Cells were activated with TransAct T cell reagent (Miltenyi Biotech) 
and transduced 24 hours post activation at an MOI of 5 and electroporated with Cas9 
mRNA on day 4.  
 
Detection of non-homologous end joining (NHEJ) events  
PCR amplicons of genomic DNA were sequenced and analyzed using TIDE protocols 
(https://tide.nki.nl/).35 (Further details in supplemental methods).  
 
FISH studies 
Translocation events involving the TRAD locus were investigated using a dual-color, 
break-apart FISH probe (Cytocell TCRAD LPH 047-S; 14q11, red/green fusion) to 
interrogate interphase nuclei. A normal signal pattern comprises 2 fusion signals and 
TRAD rearrangements exhibit segregated single red/green markers.  
 
In vitro Cytotoxicity  
Cytotoxic function of CAR19-TCR+, CAR19+TCR+ and TT-CAR19+TCR- T cells was 
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effector to target ratios (E:T in a 96 well format for 4 hours at 37°C). Release of 51Cr was 
quantified using a microplate scintillation counter and specific cytotoxicity calculated. 
 
Next Generation Sequencing  
On-target and potential off-target sites were amplified and using Phusion polymerase 
(New England BioLabs), and the resulting PCR amplicons were amplified again using 
TruSeq HT Dual Index primers to make a library. Libraries were then subjected to paired-
end sequencing using MiniSeq (Illumina).  
 
Digenome-seq 
To induce Cas9-mediated in vitro cleavage of genomic DNA, 100nM Cas9 protein and 
300nM TRAC-targeting sgRNA were incubated with 10µg genomic DNA in a reaction 
buffer of 500µl (100mM NaCl, 50mM Tris-HCl, 10mM MgCl2, 100µg/ml BSA, pH 7.9) 
at 37°C for 8 hours. Digested DNA was incubated with 50µg/ml RNase A (Qiagen) at 
37°C for 30 minutes to remove sgRNA, and purified again with a DNeasy Tissue Kit 
(Qiagen). Digested genomic DNA was fragmented with Covaris system (Life 
Technologies), and ligated with adapters to produce libraries, which were subjected to 
WGS using HiSeq X Ten Sequencer (Illumina) at Macrogen. Cas9-mediated in vitro 
cleavage of genomic DNA was performed and DNA cleavage scores were calculated 
using a scoring system described previously.17, 36 
 
Whole Genome Sequencing 
Genomic DNA was extracted from CAR19+TCR+ and TT-CAR19+TCR- cells, using the 
DNeasy Blood and Tissue Kit (QIAGEN). Approximately 1.5µg of Genomic DNA was 
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using the MiSeq platform. Overall alignment rates were >99.9% and correct pairing 
>>98.3%. GATK and DELLY were used to identify single nucleotide variance, indels and 
other structural differences. Targeted assessment of the TRAC locus and 49 predicted 
possible off-target sites was undertaken as well as screening of ten known gene sites 
where translocations of 14q have known leukemic associations. 
 
In vivo anti-tumor activity  
NOD/SCID/c-/- (NSG) mice, were inoculated IV with 5x105 CD19+ Daudi tumor cells 
by tail vein injection on day 0. The tumor cells had been stably transduced to express both 
enhanced green fluorescent protein (EGFP) and Luciferase. Tumor engraftment was 
confirmed by in vivo imaging of bioluminescence using an IVIS Lumina III In Vivo 
Imaging System (PerkinElmer, Massachusetts, USA, live image version 4.5.18147) on 
day 3. Animals were injected on day 4 with either PBS (n=3), 5x106 untransduced 
CAR19-TCR+ T cells (n=8), 8x106 CAR19+TCR+ T cells (n=8) or 5x106 TT-
CAR19+TCR- T cells (n=8). Analysis of tumor clearance was performed by serial 
bioluminescent imaging and processing of bone marrow for the monitoring of tumor 
progression vs clearance was carried out on days 7, 10, 14, 18, 21, 28, and 35. Bone 
marrow samples were processed by a red blood cell lysis followed by staining for flow 
cytometry. All animal studies were approved by the University College London 
Biological Services Ethical Review Committee and licensed under the Animals (Scientific 
Procedures) Act 1986 (Home Office, London, United Kingdom). (Further details in 
supplemental methods).   
Statistics 
A two-tailed Man-Whitney U test was used for non-parametric comparison of grouped 
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error of the mean (SEM) or standard deviation (SD) or as a median with the 25th and 75th 
percentiles (50% central range) stated. Linear Regression was used for the comparison of 
serial measurements, taking each Y value as an individual point. All statistical analysis 
was performed using GraphPad Prism software version 5.01.      
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Figure legends  
Figure 1. Terminal CRIPSR-CAR coupled lentiviral vector configuration. (A) 
Schema of CAR 19 expression for the targeted killing of CD19+ B cells, with 
simultaneous CRISPR mediated TCR disruption, where ideally all T cells are CAR19+ 
and TCR-  (B) Self inactivating lentiviral plasmid configuration coupling terminal TRAC 
(TT) CRISPR guide RNA and CAR19 transgene expression. A human PolIII promoter-
sgRNA CRISPR cited in the deleted unique (∆U3) region, proximal to repeat (R) 
elements of the 3’long terminal repeat (LTR).  (C) Following reverse transcription, 3’ 
LTR elements, including the PolIII-sgRNA cassette, duplicate to the 5’LTR of the 
proviral vector. (D) single-guide RNA (sgRNA) expressed from both 5’ and 3’ LTR 
vector elements forms ribonucleoprotein complexes with Cas9  following electroporation 
of Cas9 mRNA, and this effect is restricted to transduced populations. 
 CMV, Cytomegalovirus promoter; LTR: long terminal repeat; hPGK: human 
phosphoglycerate kinase promoter; cPPT: central polypurine tract; WPRE: woodchuck 
post transcriptional-regulatory element; gRNA: guide-RNA; sgRNA: single-guide RNA; 
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Figure 2. Validation of Terminal CRISPR-CAR vector and titration of Cas9-
mediated knockout effect in primary human T cells. (A) PCR amplification of proviral 
5’ LTR elements, spanning the ∆U3 and Psi regions (755bp band) and 3’LTR (742bp 
band) confirmed the presence of duplicated PolIII-sgRNA in T cells transduced with TT-
CAR19. (B) RT-qPCR measurement of TRAC sgRNA fold change at 0, 1, 3, 4, 7 and 11 
days post transduction shows stabilization of sgRNA expression after 4 days. (C) 
Quantification of TCR knockout following Cas9 mRNA electroporation of primary T 
cells at 1, 2, 3, 4, 7 or 11 days post TT-CAR19 transduction showing optimal TCR 
disruption occurring at 3-4 day time point. Percent knockout calculated by flow cytometry 
based detection of TCR expression in CAR19+ population. (D) Following Cas9 mRNA 
electroporation, Cas9 protein expression detected as a 160 kda band peaked after 12 hours 
and became undetectable by 72 hours. β-actin detection (42 kda) verified protein loading. 
(E) Coupling of transgene expression and TCR disruption effects across a gradient of 
Cas9 mRNA concentrations in TT-CAR19 transduced PBMCs exhibiting >70% CAR19 
expression. (F) PCR amplification and analysis by TIDE algorithm for the detection of 
NHEJ signatures across the TRAC locus confirmed Cas9 dose dependent scission and 
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Figure 3. Scalability and in vitro functional integrity of TT-CAR19+TCR- T cells. 
(A) Scaled manufacture of homogenous TT-CAR19+TCR- cells using a semi-automated 
process on a CliniMACS Prodigy device in combination with off-device electroporation. 
Control cultures were separated and cultured in G-Rex 10 flasks at relevant stages. 
Following anti-CD3/anti CD28 activation, lentiviral, transduction and Cas9 mRNA 
electroporation, T cells were expanded in the integrated cultivation chamber before 
magnetic bead depletion of residual TCRαβ cells. As a consequence, coupled TCR 
knockout effects and CAR expression was assured in the final product. (B) Flow 
cytometry of untransduced (UTD) and cells transduced with TT-CAR19 but not supplied 
with Cas9 provided comparator data. Addition of Cas9 mRNA by electroporation resulted 
TCR loss in >52% of cells, and this population was enriched to >99% by TCRαβ 
depletion using magnetic beads. The resulting population was >97%CAR19+. (C) PCR 
amplification and analysis by TIDE algorithm of the TRAC locus in TT-CAR19 T cells 
with and without Cas9 mRNA electroporation confirming on-target NHEJ repair 
signatures. (D) Comparable CD19 specific cytotoxicity against 51Cr labelled CD19+ 
SupT1 cells across a range of CAR19+ Effector:Target ratios was detected for 
CAR19+TCR+ (green) and TT-CAR19+TCR- effectors (red) (P=0.4461) but not for 
UTD CAR19-TCR+ populations (blue) (P<0.0001), indicating intact effector function 
after the additional processing steps required to generate universal cells. CD19- control 
targets confirmed specificity (dotted lines) P< 0.0001. Error bars represent standard error 
of the mean (n=3). Linear regression analysis showed significance between CAR19-
TCR+ and CAR19+TCR+ (F=70.37, DFn=1, DFd=36, P<0.0001) or TT-CAR19+TCR- 
(F=47.65, DFn=1, DFd=44, P<0.0001) effectors against CD19+ Supt1 targets. No 
significance seen between CAR19+TCR+ and TT-CAR19+TCR- effectors (F=0.59, 
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cytometry were also comparable in CAR19+TCR+ and TT-CAR19+TCR- effectors when 
co-cultured with CD19+ Daudi targets. PMA and ionomycin stimulation of TT-
CAR19+TCR- effectors served as positive controls for the detection of HLA-DR, IFNγ, 
CD107a and CD25. Error bars represent SEM of technical replicates (n=3).  (F) Flow 
cytometric detection of cytokines in supernatant from co-cultures with SupT1 targets 
found comparable levels of IFNγ and TNFα for CAR19+TCR+ and TT-CAR19+TCR- 
effectors. Error bars represent SEM of technical replicates (n=3).  
  
Figure 4. Off-target analysis by FISH, Digenome-seq and WGS. (A) TRAD FISH 
probe (Cytocell) – red centromeric end - green telomeric end to the TCR gene. Two 
fusions (green/red) present showed no rearrangement of the TRAD locus in TT-
CAR19+TCR-(+Cas9) treated samples. (B) Digenome-seq captured on-target cleavage of 
the TRAC locus, chr14. Straight alignment in TRAC sgRNA SpCas9 digested DNA 
indicated on-target cleavage of the TRAC locus compared to staggered alignment of 
untreated DNA. (C) On- and off-target capture by Digenome-seq in TRAC sgRNA 
SpCas9 treated DNA displaying on-target cleavage (chr14) and off-target events in chr7 
and chr15. (D) Cleavage scores in 12 chromosomal locations captured by Digenome-seq 
as off-targets in TRAC sgRNA SpCas9 treated DNA. High-resolution NGS-based 
validation of captured off-target sites in TT-CAR19+TCR- DNA shows absence of off-
target Indels. (E) Genomic variants (SNVs, deletions and insertions) identified by 30X 
WGS and classed as significant by frequency of detection showed comparable counts in 
both CAR19+TCR+(-Cas9) treated and TT-CAR19+TCR-(+Cas9) treated samples. (F) 
“CRISPR-specific” Indels identified to be unique to each sample exhibit higher frequency 
in edited TT-CAR19+TCR-(+Cas9) sample. (G) Comparative frequency of structural 
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after 30X WGS analysis in CAR19+TCR+(-Cas9) treated and TT-CAR19+TCR-(+Cas9) 
samples. (H) Translocations unique to each sample as part of total reads (F) reveals minor 
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Figure 5. Human:murine leukemia responses by TT-CAR19+ effector T cells against 
CD19+GFP/Luciferase Daudi targets. (A) Serial bioluminescence imaging (BLI) of 
NSG mice following intraperitoneal administration of D-luciferin substrate. (B) Timeline 
of tumor and effector cell injection, BLI and organ harvest time points over the 5wk 
period. (C) Progressive increases in radiance [p/s/cm2/sr] in non-treated (n=3) or control 
CAR19-TCR+ (n=8) effector groups indicated leukemic progression within 2 weeks (wk) 
and resulted in death by 4wk of the three animals subjected to extended monitoring. Mice 
injected with CAR19+TCR+ (n=8) or TT-CAR19+TCR- (n=8) effectors exhibited 
significantly delayed leukemic progression by 2wk compared to CAR19-TCR+ 
(P=0.0002), as tracked for 5wks in in three animals with CAR19+TCR+ and four with 
TT-CAR19+TCR- cells. The latter exhibited the lowest disease radiance at termination 
P<0.0001, error bars represent SEM. Linear regression analysis showed significance 
amongst all groups: CAR19+TCR+ vs. CAR19-TCR+ (F=29.79, DFn=1, DFd=87, 
P<0.0001), TT-CAR19+TCR- vs. CAR19-TCR+ (F=53.77, DFn=1, DFd=92, P<0.0001), 
TT-CAR19+TCR- vs. CAR19+TCR+ (F=8.93577, DFn=1, DFd=95, P=0.0036). Dotted 
lines represent Mann-Whitney U test (*P=0.0499, ***P=0.0002). (D) Representative flow 
cytometry plots gated on human CD45+ populations in bone marrow (BM) demonstrating 
a greatly reduced, but well demarcated population of GFP+ leukemia in CAR19+TCR+ 
treated mice [n=5 (2wk)/n=3 (5wk)] compared to UTD CAR19-TCR+ cohort [n=5 
(2wk)/n=3 (4wk)]. In contrast leukemia was barely detectable in TT-CAR19+TCR- 
treated animals [n=4 (2wk)/n=4 (5wk)]. Human T cells were detected as CD2+ cells in all 
groups. (E) Disease burden after 2wk and at termination in BM was highest in control 
CAR19-TCR+ (blue circles) treated animals [(n=5 (2wk)/n=3 (4wk)]. Disease was barely 
detected in TT-CAR19+TCR- (red triangles) animals [(n=4 (2wk)/n=4 (5wk)), and found 
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[(n=5 (2wk)/n=3 (5wk)) at termination when compared to CAR19-TCR+ 2wk values 
(P=0.0357 vs. P=0.0159), error bars represent SEM. (F) Phenotypic assessment of 
leukemia in BM at termination uncovered the emergence of CD19-CD20+ Daudi 
populations in animals treated with CAR19+TCR+ cells (n=3), whereas the leukemia 
detected in control animals CAR19-TCR+ (n=3) was CD19+CD20 and the paucity of 
leukemia cells in TT-CAR19+TCR- animals (n=4) precluded further characterisation. (G) 
Representative flow cytometric data from CAR19-TCR+ [(n=5 (2wk)/n=3 (5wk)), 
CAR19+TCR+ [(n=5 (2wk)/n=3 (4wk)) or TT-CAR19+TCR- [(n=4 (2wk)/n=4 (5wk)) 
treated animals showing PD1 expression on T cells. Markedly increased expression in 
CAR19-TCR+ and CAR19+TCR+ T cell injected groups measured at 2wk and at 
termination compared to initial expression levels in cells measured in vitro (CAR19-
TCR+: 20.4%; CAR19+TCR+: 20.5%; TT-CAR19+TCR-: 9.7%) before infusion into 
mice. CAR19+TCR+ cells showed the highest increase in PD1 at termination over 
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Georgiadis et al. combine a lentiviral chimeric antigen receptor (CAR) vector with 
CRISPR guides incorporated into the 3’LTR with transient Cas9 mRNA delivery for 
coupled gene modification effects. Processing through an automated platform to 
remove residual TCRαβ-cells was scalable and yielded highly enriched ‘universal’ T-
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TRAC chr14 TCTCTCAGCTGGTACACGGCAGG 82.9 92.37 
OT1 chr7 TCTCagAGCTGGTACACaGCAGG 15.5 0.01 
OT2 chr15 TCTCatAGCTGGTACAtGGCGGG 6.9 0.02 
OT3 chr8 TCTCaCAGCTGGaACACaGCAGG 3.6 0.00 
OT4 chr1 cCcCTCAGCaGGTACACaGCCGG 1.9 0.00 
OT5 chr1 agcCagAGCTGGTACACGGCTGG 1.9 0.01 
OT6 chr7 ctgCTCAGCTGGTACACaGaAGG 1.3 0.01 
OT7 chr1 gCTCTCAcCTGGTACACaGtGGG 0.7 0.00 
OT8 chr12 ggaCTCAGaTGGcACACGGCAGG 0.5 0.01 
OT9 chr1 TtTCTCAGCTGGTACAtGGaGGG 0.4 0.02 
OT10 chr10 cCTCTCAGaTGGcACACGaCTGG 0.2 0.01 
OT11 chr16 gggCaCAGCTGGTACACaGCAGG 0.1 0.00 
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